Daily evidence digest

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Post-acute COVID-19 syndrome, mixed prime-boost vaccines, vaccine effectiveness against variant B.1.617.2 (India)

Peer reviewed journals featured:

- A systematic review on post-acute COVID-19 syndrome [here]
- A randomised controlled trial on ivermectin with doxycycline for treating COVID-19 symptoms [here]
- Observational studies on:
  - Nasopharyngeal swab, saliva, and oral-self sampling swab for SARS-CoV-2 [here]
  - The impact of official information on interpretation of COVID-19 test results by the public [here]
  - The COVID-19 epidemic in South Australia [here]
  - Corticosteroids for hospitalised patients with mild to critical COVID-19 [here]
  - Machine learning algorithms for predicting ICU admission and mortality [here]
  - Clinical staging in non-severe COVID-19 patients [here]
  - Maternal transfer of SARS-CoV-2 antibodies post Pfizer vaccine [here]
  - Mental health implications of plasma metabolomics in recovered COVID-19 patients [here]
- An editorial on preparing for the next pandemic [here]
- Commentaries on:
  - Health services research to address challenges of COVID-19 [here]
  - SARS-CoV-2 mutations, vaccines, and immunity [here]
  - Medico-legal risk management and triage policies during COVID-19 [here]
  - Ethical decision making during a healthcare crisis [here]
- US recommendations for use of Pfizer vaccine in people aged 12-15 years [here]

Letters and correspondence discussed:

- Sensational media reporting in coverage of COVID-19 therapies, detection, and vaccines [here]
- The risk of SARS-CoV-2 transmission via surgical electrocautery plume [here]
- SARS-CoV-2–specific IgG in children, 6 months after infection, in Australia [here]
- COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients [here]
Pre-peer review featured articles:

- Reactogenicity of homologous and heterologous prime-boost immunisation with Pfizer and AstraZeneca vaccines [here](#)
- Public health and health system impacts of SARS-CoV-2 variants of concern [here](#)
- Impact of the COVID-19 pandemic on vaccination uptake in Victoria [here](#)
- Effectiveness of COVID-19 vaccines in ‘real world’ studies in five countries [here](#)
- The effect of adding saliva samples to oropharyngeal and deep nasal swabs on SARS-CoV-2 detection in paediatric and primary care in Victoria [here](#)

Guidance and reports

- The US Centers for Disease Control and Prevention updated public health recommendations for fully vaccinated people [here](#)
- A joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of AstraZeneca vaccine [here](#)
- The Cochrane Library released updates on:
  - Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19 [here](#)
  - Critical care clinical answers [here](#)

News and blogs

- UK cases of variant from India rise by 160% in a week [here](#)
- Factors determining how well countries responded to the pandemic [here](#)
- The communication challenge of COVID-19 vaccine safety [here](#)
- Oral health and severe COVID-19 disease [here](#)
- A blood marker of COVID-vaccine efficacy [here](#)
- Vaccines highly effective against B.1.617.2 variant after 2 doses [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.